In this study, data show that genotype and response to ursodeoxycholic acid therapy predicted native liver survival in patients with PFIC3 (progressive familial intrahepatic cholestasis type 3). Here, ABCB4 is linked to progressive familial intrahepatic cholestasis type 3.